Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Lung Neoplasms 18Carcinoma, Non-Small-Cell Lung 18Breast Neoplasms 6Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Mesothelioma, Malignant 4Colonic Neoplasms 4Carcinoma, Ovarian Epithelial 4Carcinoma, Renal Cell 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Melanoma 2Kidney Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1

Interventions

pembrolizumab 48Nivolumab 22Cyclophosphamide 10Carboplatin 10spartalizumab 8atezolizumab 7Gemcitabine 7130-nm albumin-bound paclitaxel 7fludarabine 6Cisplatin 6Ipilimumab 5durvalumab 4budigalimab 4avelumab 4Pemetrexed 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Irinotecan 4Interleukin-2 4Immune Checkpoint Inhibitors 4Docetaxel 4Bevacizumab 4cemiplimab 3cabozantinib 3aldesleukin 3Standard of Care 3Specimen Handling 3Oxaliplatin 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × sargramostim × Thoracic × Clear all
NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡